Antiproliferative Activity of α-Tomatine and Molecular Target Identification

Yıl 2020, Cilt: 7 Sayı: 2, 290 - 300, 24.04.2020

Halil I. Cıftcı

https://doi.org/10.30910/turkjans.706098

Cited By: 2

Öz

α-tomatine is a glycoalkaloid derived from tomato varieties that has been reported to possess various anticancer properties. However, its inhibitory effects on epidermal growth factor receptor is still poorly understood. The aim of this study is to investigate the anticancer effect of α-tomatine and its related mechanisms in lung cancer cells. Cytotoxicity and apoptosis induction of α-tomatine were determined by MTT assay and annexin V-FITC staining methods, respectively. For tyrosine kinase activity, TK-1 kinase selectivity profiling assay and molecular modelling study were performed. The DNA cleavage activity of α-tomatine was investigated using agarose gel electrophoretic method. α-tomatine proved to possess an outstanding antiproliferative activity against A549 and Jurkat cells without noticeable toxicity on PBMC. The results indicated that α-tomatine has a significant inhibition effect on both EGFR and HER2. α-tomatine formed some key interaction into ATP binding sites of EGFR and HER2. Furthermore, α-tomatine strongly disintegrated DNA at low concentrations in the presence of iron(II) complexes. The current findings suggest that α-tomatine has a distinguished receptor tyrosine kinase inhibition profile from erlotinib and might be a potential drug candidate for treatment of NSCLC.

Anahtar Kelimeler

α-Tomatine, Lung cancer

Destekleyen Kurum

The work was supported by Project P16111 from Japan Society for the Promotion of Science (JSPS).

Teşekkür

The author thanks Prof. Masami Otsuka and Prof. Dr. Mikako Fujita for helpful the discussions on molecular modeling and English editing.

α-Tomatin`nin Antiproliferatif Aktivitesi ve Moleküler Hedef Tanımlaması

Öz

Domates çeşitlerinden elde edilen bir glikoalkaloid olan α-tomatin`nin çeşitli antikanser özelliklere sahip olduğu bildirilmiştir. Fakat, onun epidermal büyüme faktörü reseptörü üzerindeki inhibitör etkileri hala tam olarak anlaşılamamıştır. Bu çalışma, α-tomatin`nin akciğer kanser hücreleri üzerindeki antikanser etkisi ve ilgili mekanizmalarını araştırmayı amaçlamaktadır. α-tomatin`nin sitotoksisitesi ve apoptoz tetiklenmesi sırasıyla MTT ve anneksin V-FITC boyama yöntemleriyle belirlendi. Tirozin kinaz aktivitesi için, sırasıyla TK-1 kinaz seçicilik profil tahlili ve moleküler modelleme çalışmaları yapıldı. α-tomatin`nin DNA parçalanma aktivitesi, agaroz jel elektroforezi yöntemi kullanılarak araştırıldı. α-tomatin`in A549 ve Jurkat hücrelerine karşı üstün bir antiproliferatif aktiviteye sahip olduğu ve PBMC'de gözle görülür toksisitesinin olmadıgı kanıtlandı. Sonuçlar, α-tomatin`nin hem EGFR hem de HER2 kinazların üzerinde önemli bir inhibisyon etkisine sahip olduğunu gösterdi. α-tomatin, EGFR ve HER2'nin ATP bağlayıcı bölgelerine bazı önemli etkileşimler meydana getirdi. Ayrıca, α-tomatin, düşük konsantrasyonlarda, demir(II) kompleksleri varlığında, DNA`yı güçlü bir şekilde parçalamıştır. Mevcut bulgular α-tomatin`nin erlotinib'den ayırt edici bir reseptör tirozin kinaz inhibisyon profiline sahip olduğunu ve KHDAK tedavisi için potansiyel bir ilaç adayı olabileceğini göstermektedir

Anahtar Kelimeler

α-Tomatin, Akciğer kanseri

Kaynakça

• Ali, T. F. S., Ciftci, H. I., Radwan, M. O., Koga, R., Ohsugi, T., Okiyama, Y., Honma, T., Nakata, A., Ito, A., Yoshida, M., Fujita, M., Otsuka, M. 2019. New SIRT2 inhibitors: Histidine-based bleomycin spin-off. Bioorgan Med Chem, 27, (9), 1767-1775.
• Arkhipov, A., Shan, Y. B., Kim, E. T., Dror, R. O., Shaw, D. E. 2013. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Elife, 2.
• Banappagari, S., Corti, M., Pincus, S., Satyanarayanajois, S. 2012. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. J Biomol Struct Dyn, 30, (5), 594-606.
• Bayrak, N., Yildirim, H., Yildiz, M., Radwan, M. O., Otsuka, M., Fujita, M., Tuyun, A. F., Ciftci, H. I., 2019. Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents. Bioorg Chem, 92.
• Chan, B. A., Hughes, B. G. M. 2015. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer R, 4, (1), 36-54.
• Chao, M. W., Chen, C. H., Chang, Y. L., Teng, C. M., Pan, S. L. 2012. Alpha-Tomatine-Mediated Anti-Cancer Activity In Vitro and In Vivo through Cell Cycle- and Caspase-Independent Pathways. Plos One, 7, (9), 1-13.
• Ciftci, H. I., Bayrak, N., Yildirim, H., Yildiz, M., Radwan, M. O., Otsuka, M., Fujita, M., Tuyun, A. F. 2019. Discovery and structure-activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells. Arch Pharm.
• Ciftci, H. I., Ozturk, S. E., Ali, T. F. S., Radwan, M. O., Tateishi, H., Koga, R., Ocak, Z., Can, M., Otsuka, M., Fujita, M. 2018. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities. Biol Pharm Bull, 41, (4), 570-574.
• Ciftci, H.I., Radwan, M. O., Ozturk, S.E., Ulusoy, N. G., Sozer, E., Ellakwa, D. E., Ocak, Z., Can, M., Ali, T. F. S., Abd-Alla, H. I., Yayli, N., Tateishi, H., Otsuka, M., Fujita, M. 2019. Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity. Molecules, 24, (19), 1-15.
• Citri, A., Yarden, Y. 2006. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Bio, 7, (7), 505-516.
• Denisenko, T. V., Budkevich, I. N., Zhivotovsky, B. 2018. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis, 9.
• Dong, Q. J., Yu, P. F., Ye, L., Zhang, J. Z., Wang, H. B., Zou, F. X., Tian, J. W., Kurihara, H. 2019. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations. Sci Rep-Uk, 9.
• Goebel, C., Louden, C. L., Mckenna, R., Onugha, O., Wachtel, A., Long, T. 2019. Diagnosis of Non-small Cell Lung Cancer for Early Stage Asymptomatic Patients. Cancer Genom Proteom, 16, (4), 229-244.
• Hou, X. J., Zhang, L., Han, L. S., Ge, J., Ma, R. J., Zhang, X. S., Moley, K., Schedl, T., Wang, Q. 2015. Differing roles of pyruvate dehydrogenase kinases during mouse oocyte maturation. J Cell Sci, 128, (13), 2319-2329.
• Huang, H. R., Chen, S. H., Van Doren, J., Li, D. L., Farichon, C., He, Y., Zhang, Q. Y., Zhang, K., Conney, A. H., Goodin, S., Du, Z. Y., Zheng, X. 2015. Alpha-tomatine inhibits growth and induces apoptosis in HL-60 human myeloid leukemia cells. Mol Med Rep, 11, (6), 4573-4578.
• Ibrahim, M. A., El-Alfy, A. T., Ezel, K., Radwan, M. O., Shilabin, A. G., Kochanowska-Karamyan, A. J., Abd-Alla, H. I., Otsuka, M., Hamann, M. T. 2017. Marine Inspired 2-(5-Halo-1H-indol-3-yl)-N, N-dimethylethanamines as Modulators of Serotonin Receptors: An Example Illustrating the Power of Bromine as Part of the Uniquely Marine Chemical Space. Mar Drugs, 15, (8).
• Inamura, K. 2017. Lung Cancer: Understanding its Molecular Pathology and the 2015 WHO Classification. Front Oncol, 7.
• Ishikawa, T., Seto, M., Banno, H., Kawakita, Y., Oorui, M., Taniguchi, T., Ohta, Y., Tamura, T., Nakayama, A., Miki, H., Kamiguchi, H., Tanaka, T., Habuka, N., Sogabe, S., Yano, J., Aertgeerts, K., Kamiyama, K. 2011. Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold. J Med Chem, 54, (23), 8030-8050.
• Kanthala, S., Banappagari, S., Gokhale, A., Liu, Y. Y., Xin, G., Zhao, Y. F., Jois, S. 2015. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer. Chem Biol Drug Des, 85, (6), 702-714.
• Koga, R., Radwan, M. O., Ejima, T., Kanemaru, Y., Tateishi, H., Ali, T. F. S., Ciftci, H. I., Shibata, Y., Taguchi, Y., Inoue, J., Otsuka, M., Fujita, M. 2017. A Dithiol Compound Binds to the Zinc Finger Protein TRAF6 and Suppresses Its Ubiquitination. Chemmedchem, 12, (23), 1935-1941.
• Koinis, F., Kotsakis, A., Georgoulias, V. 2016. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer R, 5, (1), 39-50.
• Lee, K. R., Kozukue, N., Han, J. S., Park, J. H., Chang, E. Y., Baek, E. J., Chang, J. S., Friedman, M. 2004. Glycoalkaloids and metabolites inhibit the growth of human colon (HT29) and liver (HepG2) cancer cells. J Agr Food Chem, 52, (10), 2832-2839.
• Lee, S. T., Wong, P. F., Cheah, S. C., Mustafa, M. R. 2011. Alpha-Tomatine Induces Apoptosis and Inhibits Nuclear Factor-Kappa B Activation on Human Prostatic Adenocarcinoma PC-3 Cells. Plos One, 6, (4).
• Liu, S. W., Li, S., Hai, J., Wang, X., Chen, T., Quinn, M. M., Gao, P., Zhang, Y. X., Ji, H. B., Cross, D. A. E., Wong, K. K. 2018. Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. Clin Cancer Res, 24, (11), 2594-2604.
• Liu, Q., Yu, S. N., Zhao, W. H., Qin, S., Chu, Q., Wu, K. M. 2018. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer, 17.
• Park, J. H., Liu, Y. T., Lemmon, M. A., Radhakrishnan, R. 2012. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J, 448, 417-423.
• Prabhakar, C. N. 2015. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer R, 4, (2), 110-118.
• Radwan, M. O., Ciftci, H. I., Ali, T. F. S., Ellakwa, D. E., Koga, R., Tateishi, H., Nakata, A., Ito, A., Yoshida, M., Okamoto, Y., Fujita, M., Otsuka, M. 2019. Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement. Molecules, 24, (18).
• Radwan, M. O., Koga, R., Hida, T., Ejima, T., Kanemaru, Y., Tateishi, H., Okamoto, Y., Inoue, J., Fujita, M., Otsuka, M. 2019. Minimum structural requirements for inhibitors of the zinc finger protein TRAF6. Bioorg Med Chem Lett, 29, (16), 2162-2167.
• Riely, G. J.; Yu, H. A., EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res 2015, 21, (10), 2221-2226.
• Shida, W., Tateishi, H., Tahara, Y., Fujita, M., Husham Majeed Alsaadi, D., Watanabe, M., Koga, R., Radwan, M. O., Ciftci, H. I., Gezici, S., Kurauchi, Y., Katsuki, H., Otsuka, M., Sugimura, K., Wada, M., Sekeroglu, N., Watanabe, T. 2019. Antileukemic Activity of Twig Components of Caucasian Beech in Turkey. Molecules, 24, (21).
• Shieh, J. M., Cheng, T. H., Shi, M. D., Wu, P. F., Chen, Y., Ko, S. C., Shih, Y. W. 2011. Alpha-Tomatine Suppresses Invasion and Migration of Human Non-Small Cell Lung Cancer NCI-H460 Cells Through Inactivating FAK/PI3K/Akt Signaling Pathway and Reducing Binding Activity of NF-kappa B. Cell Biochem Biophys, 60, (3), 297-310.
• Shih, Y. W., Shieh, J. M., Wu, P. F., Lee, Y. C., Chen, Y. Z., Chiang, T. A. 2009. Alpha-Tomatine inactivates PI3K/Akt and ERK signaling pathways in human lung adenocarcinoma A549 cells: Effect on metastasis. Food Chem Toxicol, 47, (8), 1985-1995.
• Sucha, L., Hroch, M., Rezacova, M., Rudolf, E., Havelek, R., Sispera, L., Cmielova, J., Kohlerova, R., Bezrouk, A., Tomsik, P. 2013. The cytotoxic effect of alpha-tomatine in MCF-7 human adenocarcinoma breast cancer cells depends on its interaction with cholesterol in incubation media and does not involve apoptosis induction. Oncol Rep, 30, (6), 2593-2602.
• Sun, S., Schiller, J. H., Spinola, M., Minna, J. D. 2007. New molecularly targeted therapies for lung cancer. J Clin Invest, 117, (10), 2740-2750.
• Takeda, M., Nakagawa, K. 2019. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci, 20, (1).
• Tan, C. S., Kumarakulasinghe, N. B., Huang, Y. Q., Ang, Y. L. E., Choo, J. R. E., Goh, B. C., Soo, R. A. 2018. Third generation EGFR TKIs: current data and future directions. Mol Cancer, 17.
• Tang, J., Salama, R., Gadgeel, S. M., Sarkar, F. H., Ahmad, A. 2013. Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol, 4. Tateishi, H., Monde, K., Anraku, K., Koga, R., Hayashi, Y., Ciftci, H. I., DeMirci, H., Higashi, T., Motoyama, K., Arima, H., Otsuka, M., Fujita, M. 2017. A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis". Sci Rep-Uk, 7.
• Travis, W. D. 2015. WHO Classification of the Pathology and Genetics of Tumors of the Lung. J Thorac Oncol, 10, (9), S68-S68.
• Wang, X., Teng, F. F., Kong, L., Yu, J. M. 2016. PD-L1 expression in human cancers and its association with clinical outcomes. Oncotargets Ther, 9, 5023-5039.
• Wood, E. R., Shewchuk, L. M., Ellis, B., Brignola, P., Brashear, R. L., Caferro, T. R., Dickerson, S. H., Dickson, H. D., Donaldson, K. H., Gaul, M., Griffin, R. J., Hassell, A. M., Keith, B., Mullin, R., Petrov, K. G., Reno, M. J., Rusnak, D. W., Tadepalli, S. M., Ulrich, J. C., Wagner, C. D., Vanderwall, D. E., Waterson, A. G., Williams, J. D., White, W. L., Uehling, D. E. 2008. 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. P Natl Acad Sci USA, 105, (8), 2773-2778.
• Yang, Y. W., Wu, C. A., Morrow, W. J. W. 2004. The apoptotic and necrotic effects of tomatine adjuvant. Vaccine, 22, (17-18), 2316-2327.
• Zimmermann, S. P. a. S. 2014. Targeted therapy in SCHLOCK driven by HER 2 insertions. Transl Lung Cancer R, 3, (2), 84–88.